Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ny Scientific Corp

Neither a doctor nor a teaching hospital

Research payments

$1,266,942

141 payments

Through program year 2025, Ny Scientific Corp is reported as receiving $1,266,942 in research payments, across 141 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $135,849 27
2024 Research $328,051 34
2023 Research $123,020 34
2022 Research $183,940 32
2021 Research $100,355 5
2019 Research $395,728 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ironwood Pharmaceuticals, Inc $363,152 4 payments
  2. AbbVie, Inc. $343,615 82 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $178,879 13 payments
  4. AstraZeneca Pharmaceuticals LP $101,740 4 payments
  5. Braintree Laboratories, Inc. $89,427 10 payments
  6. Phathom Pharmaceuticals, Inc. $54,354 8 payments
  7. Eli Lilly and Company $53,023 3 payments
  8. Celgene Corporation $31,139 4 payments
  9. Genzyme Corporation $19,746 1 payment
  10. Genentech, Inc. $15,274 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. C3718-302 $363,152 4 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2B Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of A Peripherally Acting Dopamine Receptor D2/D3 Antagonist, Tak-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic Or Diabetic Gastroparesis $159,879 8 payments
  3. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) $100,519 3 payments
  4. A Study of the Efficacy and Safety of Risankizumab in Participants With Crohnx27s Disease $64,440 8 payments
  5. Nerd-301 $54,354 8 payments
  6. A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $53,194 6 payments
  7. A Multicenter, Phase 3B, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab $53,023 3 payments
  8. A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease $38,878 8 payments
  9. A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease $36,233 4 payments
  10. M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease $30,245 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record